Decompensated Liver Cirrhosis
Conditions
Interventions
High dose group:Transfusion with high dose of MSC
Low dose group:Transfusion with low dose of MSC
Sponsors
Jinan Infectious Disease Hosptial
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed as decompensated liver cirrhosis; 2. Hepatitis B/C Liver Cirrhosis After Viral Treatment, HBV/HCV Viral Loads Below Detection Level over six mouths, and the liver function remained below Child-pugh A grade or MELD score >10; 3. Other causes of cirrhosis, liver function compensatory incomplete; 4. In the past year, despite active medical treatment taken, the condition has continued to increase, at least because of cirrhosis complications such as ascites, spontaneous peritonitis, gastrointestinal bleeding, and hepatic encephalopathy in hospital over one time; 5. Need to intermittently supplement albumin and apply diuretic therapy; 6. Albumin 30%; (Prothrombin time 5 points); 7. There was no history of gastrointestinal hemorrhage within the last month and population with no high-risk portal hypertension and gastrointestinal bleeding was evaluated recently; 8. Unconditional acceptance of orthotopic liver transplantation; 9. Aged from 18 to 65 years; 10. Voluntarily signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. A malignant tumor with liver or other organs or a history of previous cancer; 2. Complications include gastrointestinal bleeding, spontaneous peritonitis, hepatic encephalopathy, hepatorenal syndrome, and Acute infection episodes; 3. Patients with severe heart, lung, kidney or blood system diseases and failure status; 4. Pregnant or lactating women; 5. Allergic constitution; 6. There is a history of alcohol abuse, drug abuse, and failure to effectively quit; 7. Patients did not participate in other clinical trials within 4 weeks; 8. Any condition, investigator believe that patients should not participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function;Liver ascites;MELD;Child-pugh; | — |
Countries
China
Contacts
Public ContactJingbo Wang
Jinan Infectious Disease Hosptial
Outcome results
None listed